We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025. In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) stands against the other biotech stocks.
No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or break your portfolio in a very small amount of time due to the nature of how important clinical trial results are for these companies.
The United Nations forecasts that the over-65 age group will grow by 150% from 800 million in 2024 to 2 billion by 2067. This “older, richer & sicker” population is expected to push global healthcare spending on medicines up 12% to $2.3 trillion by 2028. If you combine that with AI making breakthroughs in healthcare more frequent, you’ll see many more biotech stocks starting to pop to the upside over the coming years.
Methodology
For this article, I screened the top-performing biotech stocks year-to-date.
I will also mention the number of hedge fund investors in these stocks. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
A closeup of a scientist in a lab coat, mixing two liquids for a compound to treat rare diseases.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)
Number of Hedge Fund Holders In Q4 2024: 40
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is a biopharma company making medicines for people with severe rare diseases and cancer.
The stock is up significantly so far in 2025 due to advanced acquisition talks with Merck KGaA.
Furthermore, on February 11, 2025, the FDA approved GOMEKLI™ (mirdametinib), SpringWorks’ MEK inhibitor, for the treatment of adult and pediatric patients 2 years and older with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection.
With the above approval, SpringWorks was granted a rare pediatric disease priority review voucher (PRV) by the FDA.
The consensus price target of $73.2 implies 37.05% upside.
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) is up 47.80% year-to-date.
Overall, SWTX ranks 14th on our list of the biotech stocks that are skyrocketing so far in 2025. While we acknowledge the potential of SWTX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than SWTX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 20 Best AI Stocks To Buy Now and Complete List of 59 AI Companies Under $2 Billion in Market Cap
Disclosure: None. This article is originally published at Insider Monkey.